Skip to main content
Fig. 5 | Journal of Nanobiotechnology

Fig. 5

From: Engineered extracellular vesicles derived from primary M2 macrophages with anti-inflammatory and neuroprotective properties for the treatment of spinal cord injury

Fig. 5

The inflammation regulation capabilities of Cur@EVs−cl−NGF. A Schematic diagram of Cur loading into EVs−cl−NGF. B CLSM images and the STED images (enlarged illustration in the lower right corner) of Cur@EVs−cl−NGF, EVs (green), NGF (red) and Cur (blue). C In vitro Cur release of Cur@EVs−cl−NGF. D Flow cytometry analysis of primary M1 macrophages cultivated at the lower level of the Transwell™ coculture system. (Numbers indicated per cent F4/80 + , CD86 + cells). E Flow cytometry analysis of primary M2 macrophages cultivated at the lower level of the Transwell™ coculture system. (Numbers indicated per cent F4/80 + , CD206 + cells). F ELISA-based measurement of TGF-β, IL-1β, IL-6, and TNFα (pg/mL) in supernatants prepared from the culture medium. G Representative fluorescence images of the macrophage phenotypes. H Fluorescence quantitative statistical analysis of iNOS of Figure G. I Fluorescence quantitative statistical analysis of ARG-1 of Figure G. * at the top of each group's statistical graph indicates the difference analysis with the PBS group. Data presented the mean ± SD (n = 6 per group) (*P < 0.05, **P < 0.01, ***P < 0.001 and ns not significant)

Back to article page